Type 2 Diabetes: Jardiance ® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials

Type 2 Diabetes: Jardiance ® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news